Kindred Biosciences — Investor Presentation (September 2018)
41 slides from Kindred Biosciences's investor presentation, Sep 4, 2018
Slide 1: KindredBio: Best Medicines for Our Best Friends
(Kindred Bio Best Medicines for Our Best Fri
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS T h i s p r e s e n t a t i o n c o n t a i n s f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g of t h e U . S . P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t of 1 9 9 5 . A l l s t a t e m e n t s c o n t a i n e
Slide 3: KindredBio At-a-Glance
KINDREDBIO AT-A-GLANCE One of the only veterinary biopharmaceutical companies in the world Innovative therapies leveraging validated human drugs in high growth, underserved market Commercial-stage firm with rich pipeline that offers attractive ROI potential Industry-leading biologics capabilities –
Slide 4: Our Strategy: Repurpose Human Drugs for Pets
OUR STRATEGY: REPURPOSE HUMAN DRUGS FOR PETS Pursue molecules already Average of $5-8M to develop known to work each drug in 3-6 years Reduce technical risk Portfolio approach Shorten timelines Reduce financial risk 4
Slide 5: Commercial-Stage and Attractive ROI Potential
COMMERCIAL-STAGE With a rich pipeline, our goal is to launch an average of two drugs per year ATTRACTIVE ROI POTENTIAL Market sizes are 10 times smaller than human markets but the cost of development is 100 times lower 5
Slide 6: We Spend Generously on Pets
WE SPEND GENEROUSLY ON PETS $ 6 9 . 4 $ 1 . 5 $700 B I L L I O N B I L L I O N M I L L I O N We spend $69.4 We spend $1.5 We spend $700 billion a year on billion a year on million a year on pets knee surgeries for Valentine’s Day dogs presents for pets Sources: 2017-2018 APPA National Pet Owners Sur
Slide 7: Because Pets Are Family
BECAUSE PETS ARE FAMILY 67 37 71 P E R C E N T P E R C E N T P E R C E N T 67% of pet 37% of pet 71% of pets sleep parents would parents would in bed with their give up their give up their pet parents vacation to pay cellphone to pay for pet emergency for pet emergency Sources: 7 American Institute
Slide 8: Veterinary Market Is Growing Rapidly
VETERINARY MARKET IS GROWING RAPIDLY 68 42 P E R C E N T P E R C E N T The veterinary care Animal health stocks market grew 68% have risen 42% in the from 2007 to 2017 past 12 months Sources: 2017-2018 APPA National Pet Owners Survey & 2007-2008 APPA National Pet Owners Survey 8 https://www.motifinv
Slide 9: High Willingness to Pay
HIGH WILLINGNESS TO PAY $11,000 $10,000 $10,200.15 $10,329.99 A recent study found that, on average, pet $9,000 owners who have both dogs and cats $8,000 would spend over $10,000 to $7,000 save one of their pets from a life-threatening $6,000 v illness or disease $5,000 $4,000 $3,000 $2,000 $1,000 C
Slide 10: Low Generic Penetration
LOW GENERIC PENETRATION Generic Dispensing Rates There are very few generic companies, and no automatic substitution at the pharmacy 81% Human Many products reach peak sales several years after patent expiration 7% Companion There is no biosimilar pathway Animal Note: Companion Animal dispensing rat
Slide 11: Mirataz Important Safety Information
M I R A T A Z ®️ (mirtazapine transdermal ointment) Important Safety Information: Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with
Slide 12: Mirataz now available
Mirataz® (mirtazapine transdermal ointment) now available The first and only FDA-approved transdermal medication for the management of weight loss in cats Mirataz is classified pharmacologically as a weight-gain drug 12
Slide 13: Feline Weight Loss Can Be Fatal
FELINE WEIGHT LOSS CAN BE FATAL Unintended weight loss is a leading cause of feline veterinary visits Caused by underlying conditions, such as chronic kidney disease, cancer and diabetes 9 million cats are diagnosed with unintended weight loss each year 3 million cats are currently treated for unint
Slide 14: Compliance Is Key
COMPLIANCE IS KEY 74% of veterinarians say ease of administration is a primary factor in selecting a medication for feline weight loss Mirataz® (mirtazapine transdermal ointment) is applied topically to the cat’s inner ear Provides attractive application route versus oral dosing Source: 14 2016 U.S.
Slide 15: The first and only medication for weight loss in cats
The first and only medication for: ‘weight loss in cats ~ “ANOTHER PILL? } GIVE IT TO THE DOG
Slide 16: Opportunity
OPPORTUNITY 71% of veterinarians use mirtazapine and the majority say they would switch to the transdermal gel formulation 59% 34% 7% 59% of 34% of Only 7% of veterinarians would veterinarians would veterinarians would replace most or all replace some of the not replace any mirtazapine mirtazapine m
Slide 17: Commercialization
C O M M E R C I A L I Z A T I O N
Slide 18: Companion Animal and Equine Commercialization
COMPANION ANIMAL COMMERCIALIZATION Commercialize with 20-25 person direct sales force, in conjunction with distributors EQUINE COMMERCIALIZATION Commercialize with 3-5 person direct sales force, in conjunction with distributors 18
Slide 19: World-Class Commercial Team
WORLD-CLASS COMMERCIAL TEAM 15+ YEARS >50 TOP EXPERIENCE L A U N C H E S C O M P A N I E S Sales force has Team members The team comes average have launched from top experience of over 50 products veterinary 15.7 years companies Source: 19 Data on file at Kindred Biosciences. 19
Slide 20: Deep Pipeline
D E E P P I P E L I N E
Slide 21: Deep Product Pipeline
DEEP PRODUCT PIPELINE Laboratory Field Pivotal Approval Molecule Proposed Indication Preclinical Pilot Studies Pilot Studies Study Zimeta™ Control of fever in horses Rolling NADA (dipyrone injection) Filed Zimeta™ Control of fever in horses Positive Pivotal (dipyrone oral gel) Study Control of non-r
Slide 22: Deep Product Pipeline: Other Products in Development
DEEP PRODUCT PIPELINE OTHER PRODUCTS IN DEVELOPMENT Laboratory Field Pivotal Approval Molecule Proposed Indication Preclinical Pilot Studies Pilot Studies Study KIND-014 Equine gastric ulcers Metabolic syndrome KIND-015 in horses Anti-TNF Antibody Sick newborn foals Inflammatory bowel disease Anti-T
Slide 23: Zimeta (dipyrone injection)
Z I M E T A ™️ (dipyrone injection)
Slide 24: Zimeta Opportunity
ZIMETA™️ OPPORTUNITY IV and Oral drug for the control of pyrexia (fever) in horses 8-9 million horses in the US 690,000 horses treated for fever annually Sources: The Economic Impact of the Horse Industry on the United States, 2005, American Horse Council Foundation (n=18,648 U.S. horse owners/indus
Slide 25: Zimeta Injection Pivotal Field Study Results
ZIMETA™️ (dipyrone injection) PIVOTAL FIELD STUDY RESULTS 100.0 P<0.0001 90.0 80.0 76.8 Randomized, double-blind, placebo- controlled 70.0 60.0 Primary endpoint: improvement or resolution 50.0 v of fever 40.0 NADA filed, approval expected late 2018 or Success Rate (%) 30.0 early 2019 20.0 19.4 10.0
Slide 26: Zimeta Oral Gel Pivotal Field Study Results
ZIMETA™️ (dipyrone oral gel) PIVOTAL FIELD STUDY RESULTS 100.0 P=0.0026 90.0 78.4 80.0 Randomized, double-blind, placebo- controlled 70.0 60.0 Primary endpoint: improvement or resolution 50.0 v of fever 40.0 Success Rate (%) 30.0 20.0 17.6 10.0 0.0 Placebo Zimeta Oral N=34 N=102 26
Slide 27: Zimeta Opportunity
ZIMETA™️ (dipyrone injection) OPPORTUNITY 95% 83% 95% believe that 83% would use Zimeta is a good fit Zimeta in the for their practice first year Source: 27 Zimeta Pricing Research, Ipsos Ag & Animal Health, May 2016 (n=160 U.S. equine Veterinarians) . Data on file at Kindred Biosciences. 27
Slide 28: Biologics
B I O L O G I C S
Slide 29: Biologics: The Future of Veterinary Medicine
BIOLOGICS: THE FUTURE OF VETERINARY MEDICINE Veterinary medicine to follow human market, where top drugs are biologics Industry leading biologic programs & state-of-the-art manufacturing plant Highly experienced biologics team responsible for leading human drugs End-to-end capabilities & new technol
Slide 30: epoCat Feline Erythropoietin
epoCat™ FELINE ERYTHROPOIETIN Recombinant long-acting feline erythropoietin for non-regenerative anemia in cats Half of elderly cats develop kidney disease, which can cause anemia Initial laboratory study has been completed and the results were positive, as evidenced by an increase in new red blood
Slide 31: Key Focus Area: Atopic Dermatitis
KEY FOCUS AREA ATOPIC DERMATITIS Canine atopic dermatitis, an allergic skin disease, is a >$500M a year market and growing KindredBio has an industry-leading portfolio of atopic dermatitis candidates 31
Slide 32: Canine Atopic Dermatitis: IL31 Antibody and Other Candidates
CANINE OTHER CANDIDATES - IL31 ANTIBODY ATOPIC DERMATITIS Second generation antibody that blocks Initial pilot studies of IL17 antibody, and IL31, a mediator of itching IL13/IL4 SINK have also been completed and the molecules were well tolerated Fully caninized and high affinity KindredBio has multi
Slide 33: Corporate Info
C O R P O R A T E I N F O
Slide 34: Select Summary Financials
SELECT SUMMARY FINANCIALS June 30, 2018 Operating expenses Quarter Year-to-Date Research and Development $5.8 $11.1 General and Administrative $5.8 $10.7 Total cash operating expenses $10.2 $18.9 (excluding stock-based compensation) Total operating expenses $11.6 $21.8 (including stock-based compens
Slide 35: Capital Structure and Stock History
CAPITAL STRUCTURE AND STOCK HISTORY Shares outstanding 1 33.8M Options2 5.7M Market Cap3 US$503.6M Analyst Coverage Alliance Global Partners • Ben Haynor • bhaynor@allianceg.com B. Riley FBR • Andrew D'Silva • adsilva@brileyfbr.com Cantor Fitzgerald • Brandon Folkes • brandon.folkes@cantor.com CL Ki
Slide 36: News Flow
NEWS FLOW IL31 – Results from pilot effectiveness epoCat™ – Pilot studies efficacy results Late 2018 / Early 2019 2019 Late 2019 2018 Zimeta™ IL4/IL13 – Pilot (dipyrone injection) efficacy results 36
Slide 37: Summary
S U M M A R Y
Slide 38: Summary
SUMMARY KindredBio develops innovative therapies for companion animals by leveraging validated human drugs. The markets are ten times smaller than human markets, but the cost of development is a hundred times lower. KindredBio plans to launch an average of two drugs per year. 38
Slide 39: Slide 39
Slide 40: Prescribing Information: Mirataz
Prescribing Information (nitazg TTS tend Mirataz™ (mitazapine transdermal ointme
Slide 41: Prescribing Information
Prescribing Information (nitazg TTS tend
Kindred Biosciences — Investor Presentation (September 2018) on 6ix